Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 10/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.56 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.56 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.45 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29422878 | 1.00 | PIK3CD (0.59) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL356503 | 1.00 | PIK3CD (0.59) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL16677425 | 0.90 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL356882 | 0.90 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL16677683 | 0.90 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL16677613 | 0.90 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL16677517 | 0.90 | PIK3CB (0.64) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL16677377 | 0.90 | PIK3CB (0.64) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL16677265 | 0.90 | PIK3CB (0.64) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL357282 | 0.89 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | claimed |
| US-20240025923-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS INC (US) | 2024-01-25 | — | — | US | claimed |
| US-20230183262-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | claimed |
| WO-2023086399-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | claimed |
| EP-4146660-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | claimed |
| US-20220241281-A1 | Imidazopyrimidine Derivatives | GILEAD SCIENCES, INC. | 2022-08-04 | — | — | US | claimed |
| WO-2021226262-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | claimed |
| EP-3873608-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS HAVING HPK1 INHIBITORY ACTIVITY | GILEAD SCIENCES, INC. (US) | 2021-09-08 | — | — | EP | claimed |
| EP-3873903-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-09-08 | — | — | EP | claimed |
| WO-2020237025-A1 | SUBSTITUTED EXO-METHYLENE-OXINDOLES WHICH ARE HPK1/MAP4K1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2020-11-26 | — | — | WO | claimed |
| EP-2612862-A2 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2013-07-10 | — | — | EP | claimed |
| EP-2579878-A1 | METHODS OF TREATING HEMATOLOGICAL DISORDERS WITH QUINAZOLINONE COMPOUNDS IN SELECTED PATIENTS | Gilead Calistoga LLC (US) | 2013-04-17 | — | — | EP | claimed |
| US-20120015964-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2012-01-19 | — | — | US | claimed |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | ICOS CORPORATION (US) | 2008-11-06 | — | — | US | claimed |
| EP-1761540-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2007-03-14 | — | — | EP | claimed |
| EP-1750715-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2007-02-14 | — | — | EP | claimed |
| US-20060106038-A1 | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells | ICOS CORPORATION (US) | 2006-05-18 | — | — | US | claimed |
| US-20060079538-A1 | Methods for inhibiting angiogenesis | VANDERBILT UNIVERSITY | 2006-04-13 | — | — | US | claimed |
| WO-2005120511-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2005-12-22 | — | — | WO | claimed |
| WO-2005113556-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2005-12-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220241281-A1 | Imidazopyrimidine Derivatives | DPYD, KRAS, ABL1 | PIK3CD 154/4885PIK3CG 433/4885PIK3CB 167/4885 |
| US-20060079538-A1 | Methods for inhibiting angiogenesis | FLT4, KDR, PDGFRB | PIK3CD 6/4885PIK3CG 13/4885PIK3CB 14/4885 |
| US-20060106038-A1 | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells | MCL1, NFATC1, MKI67 | PIK3CD 25/4885PIK3CG 57/4885PIK3CB 37/4885 |
| US-20230183262-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | HIPK1, HPGDS, HIPK3 | PIK3CD 2727/4885PIK3CG 3429/4885PIK3CB 2522/4885 |
| US-20120015964-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | PIK3CD 1/4885PIK3CG 4/4885PIK3CB 5/4885 |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | HIPK1, HPGDS, HIPK3 | PIK3CD 2727/4885PIK3CG 3429/4885PIK3CB 2522/4885 |
| US-20240025923-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, HIPK2 | PIK3CD 2395/4885PIK3CG 2700/4885PIK3CB 1926/4885 |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | PIK3CD, PIK3CA, PI4KA | PIK3CD 1/4885PIK3CG 4/4885PIK3CB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.